Abstracts tagged "treatment"

Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: 575 • 2018 ACR/ARHP Annual Meeting
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Elliot Hepworth², Reza Mirza², Angela Cesta³, Maggie Larche⁴ and Claire Bombardier^1,5,6, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ³Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁴Medicine, McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However,…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Nancy A. Shadick¹, Michael E Weinblatt¹, Christine K Iannaccone², Michelle Frits³, Tigwa Davis⁴, Christopher Young⁴, David H. Collier⁵, Mahdi Gharaibeh⁵ and Bradley S. Stolshek⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Health Analytics, LLC, Columbia, MD, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Andreas Kerschbaumer¹, Harald Herkner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…
Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Song-Chou Hsieh¹, Yi-Hsing Chen², Wei-Sheng Chen³, Wen-Chan Tsai⁴, Jui-Chieh Hu⁵, Hsiang-Cheng Chen⁶, Jack Mardekian⁷ and Chacun Lai⁸, ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung City, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, ⁷Pfizer Global Biometrics & Data Management, NY, NY, ⁸Pfizer PFE Limited, New Taipei, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Hilde B Hammer¹, Lars Fritjof Karoliussen², Lene Terslev³, Espen A. Haavardsholm¹, Tore Kvien⁴ and Till Uhlig⁵, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark, ⁴RAID working group for EULAR, Zurich, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Yoshiya Tanaka¹, Tsutomu Takeuchi², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Yeong Wook Song⁶, Yi-Hsing Chen⁷, Mitsuhiro Rokuda⁸, Hiroyuki Izutsu⁸, Satoshi Ushijima⁸, Yuichiro Kaneko⁸, Teruaki Shiomi⁸ and Emi Yamada⁸, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁷Taichung Veterans General Hospital, Taichung City, Taiwan, ⁸Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Tsutomu Takeuchi¹, Yoshiya Tanaka², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Mitsuhiro Rokuda⁶, Hiroyuki Izutsu⁶, Satoshi Ushijima⁶, Yuichiro Kaneko⁶, Teruaki Shiomi⁶ and Emi Yamada⁶, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Stanley Cohen¹, Yoshiya Tanaka², Xavier Mariette³, Jeffrey R. Curtis⁴, Eun Bong Lee⁵, Peter Nash⁶, Kevin Winthrop⁷, Christina Charles-Schoeman⁸, Lisy Wang⁹, Connie Chen¹⁰, Kenneth Kwok¹⁰, Pinaki Biswas¹⁰, Andrea Shapiro¹¹, Ann Madsen¹⁰ and Jürgen Wollenhaupt¹², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Paris-Sud University, Le Kremlin Bicêtre, France, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Seoul National University, Seoul, Korea, Republic of (South), ⁶University of Queensland, Brisbane, Australia, ⁷Oregon Health and Science University, Portland, OR, ⁸University of California, Los Angeles, CA, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Peapack, NJ, ¹²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Jeffrey R. Curtis¹, Jürgen Wollenhaupt², Katerina Chatzidionysiou³, Sander W. Tas⁴, Lisy Wang⁵, Harry Shi⁶, María Montoro⁷, Petra Neregård⁸, Palle Dahl⁹ and Vassilis Tsekouras¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Amsterdam Rheumatology and Immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Madrid, Spain, ⁸Pfizer Inc, Stochholm, Sweden, ⁹Pfizer Inc, Ballerup, Denmark, ¹⁰Pfizer Inc, Athens, Greece
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…
Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Burkhard Moeller¹, Axel Finckh², Jose Maria Alvaro-Gracia³, Godehard Scholz¹, Daniel Aletaha⁴, Francesca Biondo⁵, Sander Strengholt⁶, Jose L Rivas⁷, Carol A Connell⁸ and Harry Shi⁹, ¹Inselspital-University Hospital, Bern, Switzerland, ²University Hospital of Geneva, Geneva, Switzerland, ³Hospital Universitario de La Princesa, Madrid, Spain, ⁴Medical University of Vienna, Vienna, Austria, ⁵Pfizer Inc, Rome, Italy, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer SLU, Madrid, Spain, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
Abstract Number: 1538 • 2018 ACR/ARHP Annual Meeting
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Lydia A Alcazar¹, Dalifer Freites Núñez¹, Isabel Hernández-Rodríguez², Judit Font Urgelles², Pia Mercedes Lois², Benjamín Fernández-Gutiérrez², Juan A Jover Jover¹ and Zulema Rosales Rosado^1,2, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In rheumatology, we are aware of the possibility to develop adverse drug reactions (ADR) to the widely used Disease Modifying Drugs (DMARD). We are…
Abstract Number: 1539 • 2018 ACR/ARHP Annual Meeting
Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
María Badilla¹, Nicia Moldenhauer², Diego Neira³, Luis Muñoz⁴ and Oscar Neira¹, ¹Rheumatology Section., Hospital del Salvador, Universidad de Chile., Santiago, Chile, ²Rheumatology Section, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ³Internal Medicine Departament, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ⁴Pharmacy Department, Hospital del Salvador, Santiago, Chile
Background/Purpose: Best treatment of Rheumatoid Arthritis (RA) requires to begin early, with a tight control, including nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs)…

« Previous Page
1
…
5
6
7
8
9
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.